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Abstract
A tumour biomarker is a characteristic that is
objectively measured and evaluated in tumour
samples as an indicator of normal biological
processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention. The
development of a biomarker contemplates distinct
phases, including discovery by hypothesis-generating
preclinical or exploratory studies, development and
qualification of the assay for the identification of the
biomarker in clinical samples, and validation of its
clinical significance. Although guidelines for the
development and validation of biomarkers are
available, their implementation is challenging, owing
to the diversity of biomarkers being developed. The
term ‘validation’ undoubtedly has several meanings;
however, in the context of biomarker research, a test
may be considered valid if it is ‘fit for purpose’. In the
process of validation of a biomarker assay, a key point
is the validation of the methodology. Here we discuss
the challenges for the technical validation of
immunohistochemical and gene expression assays to
detect tumour biomarkers and provide suggestions of
pragmatic solutions to address these challenges.
Introduction
Biomarkers are the defining facet of translational cancer
research; however, there is a great deal of confusion
about the actual definition of what a biomarker is and
what its characteristics are. Arguably, the most widely
accepted definition is the one put forward by the Bio-
markers Definitions Working Group, which defines a
biomarker as “a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention” [1]. As the defi-
nition suggests, biomarkers can be used for multiple
purposes in cancer research and measured in distinct
types of specimens, such as tissue samples as well as
peripheral blood (see, for example, circulating tumour
cells), by using several assays. Despite the existence of
excellent guidelines for the development and validation
of biomarkers [2-4], there is a great deal of confusion
when it comes to determining the validity of an assay to
detect a biomarker. The process of biomarker develop-
ment is by no means trivial; for the purpose of simpli-
city, it can be broadly divided into four main phases: (1)
discovery of a potential biomarker through hypothesis-
generating preclinical or exploratory studies; (2) devel-
opment and technical validation of the assay for the
identification of the biomarker in clinical samples; (3)
demonstration of the biomarker’s potential clinical uti-
lity, first in retrospective analyses and subsequently in
prospective studies; and (4) continued assessment of the
validity of the biomarker in routine clinical practice
(Table 1). The term ‘validation’ in the context of clinical
studies has changed dramatically over the years; cur-
rently, perhaps the most adequate definition for a valid
biomarker is a biomarker that is fit for purpose [5].
Although great emphasis is given to the discovery and
validation of the clinical significance of the biomarker,
the technical validation of assays for novel biomarkers
has not been embraced with the same enthusiasm, prob-
ably because of its more technical and apparently less
rewarding nature. Nonetheless, the process of assay vali-
dation is critical for the introduction of a new biomarker
in routine clinical practice. This minireview focuses on
the technical issues related to validation of biomarkers
analysed directly in human tumour tissue samples, with
breast cancer pathology serving as a paradigm. It should
be noted, however, that the concepts discussed in this
review are applicable to biomarkers based on other types
of samples (for example, circulating tumour cells, blood,
serum, urine and other bodily fluids).* Correspondence: caterina.marchio@unito.it1Department of Biomedical Sciences and Human Oncology, University of
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Validation: when and why?
A biomarker often fails to be incorporated into clinical
practice, not because of flawed science underpinning its
discovery but because of poor choice of the assay used
for its detection and inadequate validation of its accu-
racy [6,7]. For the successful use of a biomarker assay in
clinical practice, it is of paramount importance that the
testing of the assay employ robust reagents and be
based on a reliable and robust technology. Several false
dawns in translational research have stemmed from
attempts to introduce a technology that was not suffi-
ciently mature at the time and from the sources of tech-
nical bias not being entirely known (for example, mass
spectrometry-based serum proteomic analysis for the
diagnosis of ovarian cancer) [8,9].
Methodological validation needs to be considered both
in well-established and in new assays. In the first scenario,
as the assay is already introduced into clinical practice,
ongoing demonstration of validity through in-house and
external quality assurance schemes allows false-positive
and false-negative results to be minimised. The impor-
tance of this problem is placed in stark focus by recognis-
ing that these checks are necessary to ensure that
potentially life-extending or lifesaving therapies are not
denied to patients who may benefit from them and that
patients are not unnecessarily exposed to toxicities or
given false hope. Several initiatives have been introduced
to provide guidelines for testing the adequacy of the rou-
tine biomarker tests (that is, oestrogen receptor (ER), pro-
gesterone receptor (PR) and human epidermal growth
factor receptor 2 (HER2) tests) in breast cancer (Table 2).
In the United Kingdom, the National External Quality
Assessment Service programme organises four assess-
ments every year that include antibody testing on multi-
tissue and cell line blocks, an expert review, a confidential
report, online images and detailed analysis of data regard-
ing methods [10]. Importantly, these approaches have led
to a significant increase in the number of laboratories
offering optimal quality immunohistochemical assessment
of these markers [10]. External quality assurance does not,
however, replace the need for internal quality control mea-
sures that enable individual batches of samples to be
accepted with confidence or, alternatively, rejected. It
should also be noted that internal controls in individual
samples, represented by the presence of normal tissue
adjacent to the tumour, can be of great support to define
the validity of a test. For example, in the assessment of ER,
PR and HER2, it is crucial to select a tumour block that, in
addition to the tumour areas, also contains adjacent nor-
mal ducts or lobules which can be used as internal
controls.
The early technical validation of a new biomarker assay
is critical to minimise waste of resources, generation of
misleading results and possibly disrepute. In this context,
Table 1 Overview of the phases of biomarker development and validationa
Phase Means/instruments Main challenges and sources of bias
Discovery of a potential
biomarker
Hypothesis-generating preclinical
or exploratory studies
Selection of biomarker based on the
availability of antibodies on the market
Development and technical validation of
the assay for the identification of the
biomarker
Optimisation of IHC-based assays for
formalin-fixed, paraffin-embedded
samples
- Use of clinical samples not suitable for
the analysis (for example core biopsies instead
of surgical samples and TMA instead of
full sections)
- Lack of reliable positive and negative
controls
- Poor fixation of clinical samples
- Wrong antigen retrieval procedure
- Wrong detection method Misinterpretation
of the results
- Training/competency of the staff
- Suboptimal performance of the antibody
due to poor fixation of archival tissues
(in particular for retrospective studies)
Validation of the clinical significance
of the biomarker
First retrospective studies and
subsequent prospective studies
- Training/competency of the staff
- Use of small cohorts or large cohorts
that include series of cases in which
the biomarker has been previously validated
Continued assessment of the
validity of the biomarker in
routine practice
Internal and external quality
assurance program
- Poor participation/adhesion to the
programme
- Lack of competency of pathologists
participating in the program
- No action taken if failing quality
assurance
a Description of the phases of biomarker development and validation, and the main challenges and potential sources of bias, using immunohistochemistry-based
assays as a paradigm.
IHC: immunohistochemistry; TMA: tissue microarray.
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however, full validity is often difficult to prove, given that
these assays come directly from research assays for which
a gold standard is usually not available.
Validation of assays for novel biomarkers
Immunohistochemistry, fluorescence and chromogenic
in situ hybridisation, expression profiling, either micro-
array-based or performed by quantitative real-time
reverse transcriptase-polymerase chain reaction (qRT-
PCR), and mutation analysis represent the main techni-
ques currently being introduced into everyday practice
in pathology laboratories. Among these techniques,
immunohistochemical tests remain the most widely
used in routine practice and, importantly, in the assess-
ment of biomarkers in translational research endeavours.
We therefore focus primarily on their validation.
In the case of immunohistochemistry, a typical ‘quick
and easy’ approach is illustrated in Figure 1. It should be
noted, however, that such an approach carries with it far
more pitfalls than many investigators assume. Although
immunohistochemistry has been introduced in pathology
laboratories for more than 25 years and is a relatively user-
friendly technique, one should not forget that the results of
immunohistochemical analysis may be affected by a series
of preanalytical and analytical parameters [11-15].
Preanalytical variables are the ‘weakest link’ of immu-
nohistochemistry, as the properties of the tissues ana-
lysed and, consequently, the results, may be affected by
several factors, including the time to collection (that is,
the length of time that tissues are subjected to warm
ischaemia between removal of the tissue at surgery and
fixation), details of fixation (type of fixative agent used
and length and conditions of fixation), dehydration
steps, and conditions for paraffin-embedding (tempera-
ture of the paraffin). These preanalytical parameters are
Table 2 Examples of external quality assurance schemes for routine biomarkers employed in breast cancer pathologya
QA scheme Scope Website
ASCO/CAP To improve the accuracy of test results and ensure that
patients receive appropriate care
http://www.cap.org/
http://www.cap.org/apps/cap.portal
UK NEQAS To promote optimal patient care by facilitating the
availability of reliable laboratory investigations,
through provision of objective information on
participant performance and professional advice
and assistance where appropriate
http://www.ukneqas.org.uk/
NordiQC To promote the quality of IHC by arranging schemes
for pathology laboratories, assessing tissue stains,
giving recommendations for improvement and
providing good protocols
http://www.nordiqc.org/
Canadian
external quality
assurance
program
To systematically monitor and improve the proficiency
of IHC testing laboratories and those involved with IHC
testing nationwide
http://www.ciqc.ca/
The RCPA
Quality
Assurance
Program
To provide external proficiency testing for
histopathology laboratories in the areas of diagnostic
and technical expertise
http://www.rcpaqap.com.au/
a Names, scope and websites of the main external quality assurance schemes for breast cancer biomarkers based on immunohistochemical and in situ
hybridisation assays.
QA: quality assurance; ASCO: American Society of Clinical Oncology; CAP: College of American Pathologists; UK NEQAS: United Kingdom
External Quality Assessment Service; IHC: immunohistochemistry; NordiQC: Nordic Immunohistochemical Quality Control; RCPA: Royal College
of Pathologists of Australasia.
Technical validation of the assay:
Screen identifies new 
candidate marker
•Is the primary antibody suitable for 
formalin fixed paraffin embedded 
samples?
Search web for antibody
•Has the immunohistochemical assay 
been optimised adequately?
•Are optimal positive and negative 
controls available?
•What is the ‘gold standard’ to calibrateApply antibody to TMAs the test?
•Is the test robust and fit for purpose? 
Report/publish findings
•Do pre-analytical parameters have an 
impact on the accuracy of the test?
The new marker 
for breast cancer
•Are TMAs fit for purpose?
shows….
Figure 1 Schematic representation of the validation process of
novel biomarkers by using immunohistochemistry. A typical
scenario for biomarkers evaluated by immunohistochemistry
contemplates that new candidate markers are identified through
screen analyses. Then, if commercially available antibodies specific to
those markers are found, sections of tissue microarray (TMA) blocks
containing a large number of samples are used to prove preliminary
results. Whenever a new antibody is used to test a novel biomarker
on tissue samples, technical validation is mandatory.
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beyond the control of investigators, are most often
unrecorded, and constitute a major potential source of
bias, in particular in multicentre, retrospective studies.
For example, the time to fixation and its length have
been branded as the ‘Achilles heel’ of phosphoprotein
assessment in clinical specimens [16] as recently shown
by Pinhel and colleagues [16,17], who found consistently
significantly lower levels of the phosphoepitopes in sur-
gical specimens compared with those found in core
biopsies.
Four main analytical issues require special attention.
Antigen retrieval (that is, a method that enables immu-
nohistochemistry to be applied to formalin-fixed, paraf-
fin-embedded (FFPE) samples), type of detection system,
the choice of antibody, and the material to be used
[11-13]. Enzyme-based and heat-induced epitope retrie-
val are available, for which strict protocols should be
followed to obtain accurate results [11]. Excellent
reviews have described the pitfalls of antigen retrieval
and how they can be overcome [11-15]. Suffice it to say
that in the absence of optimal positive and negative con-
trols and a ‘gold standard’, changing antigen retrieval
settings can render a given case positive or negative.
Arguably the most challenging aspect of any immuno-
histochemical assay is the choice of antibody. Before
applying ‘research-only’ antibodies to FFPE tissues, their
sensitivity and specificity need to be determined. It should
be emphasised that this cannot be achieved merely by
evaluating the sensitivity and specificity of the antibody by
means of Western blot analysis; these parameters need to
be assessed in FFPE samples and using optimal controls
(Figure 2). It is always difficult to find the optimal balance
between sensitivity and specificity, and, in this respect, the
antigen retrieval method and antibody titration are critical,
as is the availability of optimal controls to be used as a
gold standard. One helpful and informative approach uses
in-house or publicly available expression array data sets to
identify cell lines that can be exploited as positive controls
and then to validate their use as positive controls on the
basis of qRT-PCR assay and Western blot analysis. Nega-
tive controls can be generated by siRNA (short interfering
RNA) knockdown of the gene of interest in the cell line.
Subsequently, antibody testing can be performed on FFPE
cell pellets, and finally optimisation of immunohistochem-
istry on FFPE tissues will follow (Figure 2). In this process,
the type of detected subcellular localisation may also help
the researcher understand whether the antibody is specific.
Finally, when dealing with biomarkers used in routine
diagnostic practice, audit of the results from annual work-
load can provide supporting evidence of the actual perfor-
mance of an optimised assay used in routine practice.
Another crucial aspect is the type of tissue to be used.
Tissue microarrays (TMAs) have become very popular
in studies aiming to determine the distribution of a
given marker in a cohort of samples [18,19]. Although
TMAs have proven to be excellent tools, they should be
employed for the testing of biomarkers whose expres-
sion is relatively homogeneous and should be used only
if the concordance between the results of the analysis of
a given marker on whole tissue sections and TMAs is
close. Regrettably, assessing the latter appears not to be
a common practice. It should be noted that this issue is
applicable even to well-validated tests in breast cancer
research and practice (for example, the discordant
results in the analysis of PR expression in TMAs vs.
whole tissue sections [20]).
Identification of 
cell lines as 
iti t l
g
pos ve con ro s
In house or publicly available 
expression array datasets
Validation of positive controls 
(qRT-PCR and WB)
siRNA knock-down of gene of interestPositive control
Negative control
Validation
Generation of FFPE cell pellets
Antibody testing
(Various antigen retrieval 
methods and antibody dilutions 
t t d)
CTRL
TMA
es e
Optimisation of IHC on FFPE tissues
Figure 2 Schematic representation of a suggested approach to
adopt in the optimisation of ‘research-only’ antibodies. To
generate ideal controls for the optimisation of antibodies for
immunohistochemical analysis of formalin-fixed, paraffin-embedded
tissues, we propose the use of optimal controls in the form of cell
lines. First, cell lines that overexpress the gene and protein of
interest are identified by mining publicly available databases (for
example, microarrays and proteomics). The expression of the gene
and protein in the cell lines identified as ‘overexpressors’ is validated
by Western blot analysis and quantitative real-time reverse
transcriptase-polymerase chain reaction (qRT-PCR) assay. These
validated cell lines are used as positive controls. Once this validation
step is completed, the gene of interest is silenced using validated
short interfering RNA (siRNA}. The process of gene silencing is
subsequently validated by qRT-PCR assay and Western blot analysis,
and these cells are used as negative controls. After in vitro
validation, pellets of the positive and negative control cell lines are
produced and then subjected to formalin fixation and paraffin
embedding using routine methods. These controls are then used
for optimisation of the antibody titration and choice of antigen
retrieval system. Please note that the siRNA negative control has an
internal positive control, given that the efficiency of siRNA silencing
almost never reaches 100%. In addition, multi-tumour blocks and
tissue microarrays constructed with distinct types of tissue can be
used as positive and negative controls (images of routine diagnostic
slides courtesy of CM). CTRL: control; FFPE: formalin-fixed paraffin-
embedded; IHC: immunohistochemistry; siRNA: short interfering
RNA; TMA: tissue microarray; WB: Western blot analysis.
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Gene expression profiling studies: microarrays or
micro-awry?
In recent years, microarray gene expression profiling
and its derivatives have been widely applied to the mole-
cular and biological classification of breast cancers, and
several prognostic and predictive signatures have been
reported, some of which have been introduced into clin-
ical practice (for example, Oncotype DX Breast Cancer
Assay (Genomic Health, Inc., Redwood City, CA, USA)
and MammaPrint assay (Agendia BV, Amsterdam, the
Netherlands); for reviews, please see Weigelt et al. [21],
Sotiriou and Pusztai [22], and Reis-Filho et al. [23]).
The types of analysis and the data they generate pose a
major challenge for the translation of their findings into
assays that can be used in routine clinical practice, as
the reliability, reproducibility and stability of some have
been called into question [23-25]. In terms of preanalyti-
cal variables, most of the parameters that affect immu-
nohistochemistry also affect gene expression profiling
(for example, time to tissue fixation, time to freezing,
length of fixation, type of fixative used and tissue sto-
rage). In addition, given that these technologies are
based on nucleic acid extracts from tissue homogenates,
the variable tumour content may also constitute a con-
founding factor. Cleator et al. [26] demonstrated that
varying amounts of non-neoplastic cells in samples sub-
jected to gene expression increases the error rates of
multigene predictors, providing direct evidence that the
non-tumour content of breast cancer samples has a sig-
nificant effect on gene expression profiles.
Data analysis of these ‘mega-parameter’ profiles also
poses huge challenges. Microarray technology and bioin-
formatics/statistics applied to microarray analysis have
developed at disparate speeds and this may have led to
inappropriate conclusions being drawn and contributed
to the first wave of over-optimism and, then, to the sub-
sequent wave of (over)scepticism with this type of tech-
nology experienced in the last 10 years [24]. Indeed,
when these signatures were first described, there was lit-
tle awareness of problems of data ‘overfitting’ and meth-
ods for power calculation for microarrays [21,23]. This
field has developed rapidly, however, and guidelines reg-
ulating how a therapeutically significant gene signature
should be developed and validated are now available
[27,28]. The chances of success in developing and vali-
dating gene signatures will be significantly increased if
these guidelines are strictly followed.
Conclusions
Technical validation and qualification of a biomarker
assay may not be as glamorous as biomarker discovery;
however, together they comprise the critical lynchpins
of translational cancer research. Guidelines for the
development and validation of biomarker assays are
available. It should be noted, however, that not all
aspects of these guidelines may be applicable to the
assay to be developed. In these cases, imaginative
approaches should be sought while erring on the side of
caution. To avoid waste of resources and the use or
publication of misleading data, full awareness of the
technical challenges in assessment of the robustness of
assays and careful evaluation of the context of the assay
to be developed are required [29]. Finally, in the report-
ing of the results, uncertainties should be disclosed and
all caveats ought to be voiced. While these issues are
undoubtedly challenging and consideration of the
numerous potential pitfalls may be discouraging, aware-
ness and avoidance of these problems can allow clini-
cally relevant work of great value to be conducted [29].
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